A61P 9/00
Drugs for disorders of the cardiovascular system
A61P9/00 (Drugs for disorders of the cardiovascular system) appears on 53,440 US grants and 74,200 published applications in this corpus.
Search patents in A61P- Granted patents
- 53,440
- Published applications
- 74,200
- Assignees
- 14,522
- Inventors
- 96,607
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 69 | 0 |
| 1977 | 79 | 0 |
| 1978 | 104 | 0 |
| 1979 | 107 | 0 |
| 1980 | 109 | 0 |
| 1981 | 171 | 0 |
| 1982 | 152 | 0 |
| 1983 | 131 | 0 |
| 1984 | 189 | 0 |
| 1985 | 246 | 0 |
| 1986 | 244 | 0 |
| 1987 | 304 | 0 |
| 1988 | 283 | 0 |
| 1989 | 352 | 0 |
| 1990 | 333 | 0 |
| 1991 | 367 | 0 |
| 1992 | 349 | 0 |
| 1993 | 296 | 0 |
| 1994 | 346 | 0 |
| 1995 | 491 | 0 |
| 1996 | 467 | 0 |
| 1997 | 689 | 0 |
| 1998 | 791 | 0 |
| 1999 | 780 | 0 |
| 2000 | 882 | 0 |
| 2001 | 1031 | 313 |
| 2002 | 1252 | 1680 |
| 2003 | 1296 | 2736 |
| 2004 | 1054 | 3462 |
| 2005 | 1086 | 3385 |
| 2006 | 1374 | 3421 |
| 2007 | 1445 | 3585 |
| 2008 | 1592 | 4224 |
| 2009 | 1787 | 4647 |
| 2010 | 2542 | 5317 |
| 2011 | 2550 | 4827 |
| 2012 | 2952 | 4412 |
| 2013 | 3245 | 3602 |
| 2014 | 3263 | 3607 |
| 2015 | 2846 | 3246 |
| 2016 | 2372 | 3159 |
| 2017 | 2371 | 2753 |
| 2018 | 2036 | 2540 |
| 2019 | 1864 | 2469 |
| 2020 | 1653 | 2097 |
| 2021 | 1414 | 1858 |
| 2022 | 1084 | 1663 |
| 2023 | 866 | 1567 |
| 2024 | 825 | 1486 |
| 2025 | 847 | 1324 |
| 2026 | 462 | 820 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61P 9/10Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic30,878
- A61P 9/12Antihypertensives13,592
- A61P 9/04Inotropic agents, i.e. stimulants of cardiac contraction7,424
- A61P 9/08Vasodilators for multiple indications4,519
- A61P 9/06Antiarrhythmics3,627
- A61P 9/14Vasoprotectives2,743
- A61P 9/02Non-specific cardiovascular stimulants1,614
Recent patents
- Pulmonary arterial compliance with inhaled nitric oxide (iNO) treatment6 Oct 2026US 12,751,968 B2Mallinckrodt Pharmaceuticals Ireland Limited
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Treating vasculature related diseases or disorders using nanoparticles29 Sep 2026US 12,746,212 B2The Regents of the University of California
- Mono- and bis-nitrosylated propanediols for therapeutic use29 Sep 2026US 12,746,215 B2Attgeno Bio
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Treprostinil prodrugs8 Oct 2026US 2026/0306438 A1United Therapeutics Corporation
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection8 Oct 2026US 2026/0306473 A1
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation8 Oct 2026US 2026/0306492 A1Bristol-Myers Squibb Company
- Amorphous calcium carbonate for prevention and treatment of myocardial ischemia8 Oct 2026US 2026/0306533 A1Amorphical Ltd.
Most cited
By later US patents
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Bioabsorbable sealant1,550US 6,685,727 B2Bio-SEAL, LLC · 2004
- Gum pad for delivery of medication to mucosal tissues1,140US 6,319,510 B12001
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001